STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAIA
  4. [Form 4] MAIA Biotechnology, Inc. Insider Trading Activity

MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MAIA Biotechnology director Ramiro Guerrero received a grant of stock options, acquiring rights to 26,355 shares of common stock. The options have an exercise price of $1.44 per share, vest 100% on the grant date of June 30, 2026, and are exercisable immediately through June 30, 2036.

Positive

  • None.

Negative

  • None.
Insider Guerrero Ramiro
Role null
Type Security Shares Price Value
Grant/Award Stock Options 26,355 $0.00 --
Holdings After Transaction: Stock Options — 26,355 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 26,355 options Stock options granted June 30, 2026
Underlying shares 26,355 shares Common stock underlying the options
Exercise price $1.44 per share Option exercise price
Expiration date June 30, 2036 Option term end date
Options after transaction 26,355 options Total options held following grant
Stock Options financial
"The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
2021 Equity Incentive Plan financial
"granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"
vest 100% on the date of the grant financial
"representing the right to buy shares of common stock, vest 100% on the date of the grant"
exercise price financial
"conversion or exercise price $1.4400 per share for the stock options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
exercisable financial
"and are exercisable beginning as of that date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Guerrero Ramiro
(Last)(First)(Middle)
444 WEST LAKE STREET, SUITE 1700
(Street)
CHICAGO ILLINOIS 60606
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options$1.4406/30/2026A26,35506/30/2026(1)06/30/2036Common Stock26,355$026,355D
Explanation of Responses:
1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
/s/ Ramiro Guerrero07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did MAIA (MAIA) director Ramiro Guerrero report in this Form 4?

Ramiro Guerrero reported receiving a grant of stock options for 26,355 shares of MAIA common stock. These options were granted as compensation, not bought in the open market, and give him the right to purchase shares at a fixed exercise price.

How many MAIA Biotechnology shares are covered by Guerrero’s new stock options?

The grant covers 26,355 shares of MAIA Biotechnology common stock. This figure represents the total number of underlying shares linked to the stock options reported in this Form 4, all of which vest immediately on the grant date.

What is the exercise price and term of Guerrero’s MAIA stock options?

The options carry an exercise price of $1.44 per share and expire on June 30, 2036. This means Guerrero can choose to buy MAIA common shares at $1.44 any time from June 30, 2026 until the expiration date.

When do Ramiro Guerrero’s MAIA stock options vest and become exercisable?

The options vest 100% on June 30, 2026, the grant date, and are exercisable beginning that same date. According to the footnote, the entire award is immediately vested, giving Guerrero full rights to exercise from day one.

How many MAIA stock options does Guerrero hold after this reported grant?

Following this transaction, Guerrero holds 26,355 stock options directly. This total equals the full amount granted in the award, indicating there were no prior option holdings reported in this filing’s derivative section.